Association of Trabecular Bone Score with Inflammation and Adiposity in Patients with Psoriasis: Effect of Adalimumab Therapy
Table 1
Main baseline epidemiological characteristics of the patients.
Variable
Sex (M/F), n (%)
15 (51.7)/14 (48.3)
Age at study onset (yrs.), m (SD)
38.6 (10.7)
Psoriasis duration (yrs.), median (IQR)
18 (9–27)
Current smokers, n (%)
10 (34.5)
Weight (Kg), m (SD)
78.8 (15.5)
BMI (Kg/m2), m (SD)
27.5 (3.7)
Waist perimeter (cm), m (SD)
96.1 (10.8)
Systolic BP (mm Hg), m (SD)
120.3 (12.4)
Diastolic BP (mm Hg), m (SD)
75.0 (6.8)
BSA (%), m (SD)
37.9 (16.3)
PASI, m (SD)
18.9 (7.8)
ESR (mm/1st h), median (IQR)
10 (4–21)
hs-CRP (mg/dL), median (IQR)
0.29 (0.07–0.58)
Fat percentage, (%)
32.7 (8.8)
TBS (unitless), m (SD)
1.448 (0.102)
BMI: body mass index. BP: blood pressure. BSA: percent of body surface area affected. PASI: Psoriasis Area and Severity Index. ESR: erythrocyte sedimentation rate. hs-CRP: high-sensitive C-reactive protein. TBS: trabecular bone score.
